Status:
COMPLETED
Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety and tolerability of single-dose administration of IDX719 in participants with normal hepatic function and participants wit...
Eligibility Criteria
Inclusion
- Read and sign the written informed consent form (ICF) after the nature of the study has been fully explained.
- All subjects of childbearing potential must have agreed to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug.
- Male subjects have agreed not to donate sperm from Day -1 through 90 days after the last dose of study drug.
Exclusion
- Pregnant or breastfeeding.
- Other clinically significant medical conditions or laboratory abnormalities
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01919125
Start Date
August 1 2013
End Date
February 1 2014
Last Update
January 26 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.